Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A “good response” was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DL CO) >15% and PaO 2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics. Trial registration: ClinicalTrials.gov NCT00573326. Registered 13 December 2007.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A low dose of imatinib has also been tested in an open label study for treatment of intestitial lung disease in SSc patients unresponsive to cyclophosphamide (184), and was reported to stabilize lung function but again had no effect on skin.”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 2×
“In view of these discordant data, we designed a multicenter, prospective, open-label trial with the following characteristics: only SSc patients with active lung involvement, despite previous therapy with cyclophosphamide, were enrolled; a single dose of 200 mg/day imatinib mesylate was used; the study was structured…”
MethodInfluentialStandardisation of the measurement of lung volumes
Wanger, J., Clausen, J. L., Coates, A., Pedersen, O. F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C. P. M., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035005 · Cited by 2,768 · cited 1×
“Pulmonary function tests and single-breath diffusing capacity were performed in accordance with recommended standards [20,21].”
MethodStandardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528 · cited 2×
“75 to 62) years and median disease duration (defined as the time from the onset of the first non-Raynaud’s phenomenon clinical manifestation) was 3 years [1-6].”
BackgroundGlivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389 · cited 1×
“Imatinib mesylate (Gleevec; Novartis Europharm Ltd, Wimblehurst Road, Horsham, West Sussex RH12 4AB, UK) has been approved for the therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors [7].”
BackgroundGabrielli, A., Avvedimento, E. V., & Krieg, T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0806188 · Cited by 1,384
Self-citationMahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292 · cited 2×
“The diagnosis of active lung involvement required the presence of grade 2 exertional dyspnea according to the Mahler Baseline Dyspnea Index [19] plus interstitial alveolitis assessed by high-resolution computed tomography (HRCT) scan (ground-glass opacifications involving at least two lung segments) or neutrophilic (>3”
MethodClements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
FERRI, C., VALENTINI, G., COZZI, F., SEBASTIANI, M., MICHELASSI, C., LA MONTAGNA, G., BULLO, A., CAZZATO, M., TIRRI, E., STORINO, F., et al. (2002) · Medicine · doi:10.1097/00005792-200203000-00004 · Cited by 764
Self-citationDaniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J., LIMPER, A. H., & Leof, E. B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19603 · Cited by 574 · cited 1×
“Interest in use of imatinib mesylate in SSc lies in its ability to interfere with the tyrosine kinases downstream of the receptors for transforming growth factor beta and platelet-derived growth factor, which are considered key signaling molecules in the pathogenesis of SSc fibrosis [8,9].”
BackgroundCarroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Daniels, C. E., Wilkes, M. C., Edens, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419603 · Cited by 493
Randomized phase II clinical trials.
Simon, R. M., Wittes, R. E., & Ellenberg, S. S. (1985) · PubMed · Cited by 482
Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography.
Schurawitzki, H., Stiglbauer, R., Graninger, W., Herold, C., Pölzleitner, D., Burghuber, O. C., & Tscholakoff, D. (1990) · Radiology · doi:10.1148/radiology.176.3.2389033 · Cited by 292 · cited 2×
“75 to 62) years and median disease duration (defined as the time from the onset of the first non-Raynaud’s phenomenon clinical manifestation) was 3 years [1-6].”
BackgroundMethodSeggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A. L., Cambareri, A. C., Zannettino, A. C. W., Miller, B. L., Doherty, K. V., Hughes, T. P., & Lyons, A. B. (2005) · Blood · doi:10.1182/blood-2004-10-3967 · Cited by 284 · cited 1×
“Besides plateletderived growth factor receptor α/β, the nonreceptor Abelson tyrosine kinase (c-abl) [28], stem cell factor receptor c-KIT [28], macrophage colony-stimulating factor receptor (c-fms) [29] and lymphocyte-associated kinase (lck) [30] – which are all involved in development, activation, proliferation and f…”
BackgroundSelective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28546 · Cited by 220 · cited 1×
“Furthermore, imatinib 100 mg/kg suppressed the progression and attenuated the severity of established experimental encephalomyelitis, a mouse model of multiple sclerosis [32], of autoimmune arthritis [33], and of autoimmune diabetes in mice [34].”
BackgroundTyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Louvet, C., Szot, G. L., Lang, J., Lee, M. R., Martinier, N., Bollag, G., Zhu, S., Weiss, A., & Bluestone, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810246105 · Cited by 217 · cited 1×
“Furthermore, imatinib 100 mg/kg suppressed the progression and attenuated the severity of established experimental encephalomyelitis, a mouse model of multiple sclerosis [32], of autoimmune arthritis [33], and of autoimmune diabetes in mice [34].”
BackgroundHigh resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.
Launay, D., Rémy-Jardin, M., Michon-Pasturel, U., Mastora, I., HACHULLA, E., Lambert, M., Delannoy, V., Queyrel, V., Duhamel, A., Matran, R., et al. (2006) · PubMed · Cited by 189
Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143974 · Cited by 173 · cited 3×
“This differs remarkably from the results of the other published trials, which were characterized by the poor tolerability of the treatment due to the higher doses employed [10-13].”
BackgroundResultKhanna, D., Saggar, R., Mayes, M. D., Abtin, F., Clements, P. J., Maranian, P., Assassi, S., Saggar, R., Singh, R. R., & Furst, D. E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30548 · Cited by 139 · cited 3×
“This differs remarkably from the results of the other published trials, which were characterized by the poor tolerability of the treatment due to the higher doses employed [10-13].”
BackgroundResultKhanna, D., Clements, P. J., Fürst, D. E., Chon, Y., Elashoff, R. M., Roth, M. D., Sterz, M. G., Chung, J., FitzGerald, J. D., Seibold, J. R., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20787 · Cited by 134
Interstitial lung disease in scleroderma
White, B. (2003) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(03)00025-5 · Cited by 133
Pope, J., McBain, D., Petrlich, L., Watson, S., Vanderhoek, L., de Leon, F., Seney, S., & Summers, K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30549 · Cited by 124
Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., et al. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11186.x · Cited by 105
Crespo, O., Kang, S. C., Daneman, R., Lindstrom, T. M., Ho, P. P., Sobel, R. A., Steinman, L., & Robinson, W. H. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9579-6 · Cited by 75 · cited 1×
“Furthermore, imatinib 100 mg/kg suppressed the progression and attenuated the severity of established experimental encephalomyelitis, a mouse model of multiple sclerosis [32], of autoimmune arthritis [33], and of autoimmune diabetes in mice [34].”
BackgroundThe natural course of progressive systemic sclerosis patients with interstitial lung involvement
Müsellim, B., İkitimur, H., & Öngen, G. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0302-6 · Cited by 43 · cited 2×
“75 to 62) years and median disease duration (defined as the time from the onset of the first non-Raynaud’s phenomenon clinical manifestation) was 3 years [1-6].”
BackgroundMethodDistler, O., Eich, W., Dokoupilová, E., Dvorak, Z., Fleck, M., Gaubitz, M., Hechler, M., Jansen, J., Krause, A., Bendszus, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25062 · Cited by 35
Imatinib: Novel Treatment of Immune-Mediated Kidney Injury
Wallace, E. L., & Gewin, L. S. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012080818 · Cited by 24 · cited 1×
“In this respect, imatinib has been investigated in several models of kidney disease [31] and shown to ameliorate immunologic and fibrotic features.”
BackgroundLevels of target activation predict antifibrotic responses to tyrosine kinase inhibitors
Maurer, B., Distler, A., Dees, C., Khan, K., Denton, C. P., Abraham, D., Gay, R. E., Michel, B. A., Gay, S., Distler, J. H. W., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203729 · Cited by 20 · cited 1×
“Identification of these patients is crucial, and in this respect it is reasonable to suggest that: future trials with tyrosine kinase inhibitors should include patients with less advanced lung disease – treating patients at an earlier stage could be more rewarding, as suggested by the lack of effect of imatinib on est…”
BackgroundGuo, L., Chen, X., Gu, Y., Zou, H., & Ye, S. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2032-2 · Cited by 17 · cited 1×
“Six clinical pilot trials in SSc patients have been published, with a focus on the safety and effectiveness of imatinib mesylate in the treatment of both cutaneous and pulmonary involvement [10-15].”
Background
Research works printed but not linked: 1
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliand DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 15: 4947-4952. · DOI · Paper page
Cited by
Spagnolo, P., Distler, O., Ryerson, C. J., Tzouvelekis, A., Lee, J. S., Bonella, F., Bouros, D., Hoffmann-Vold, A.-M., Crestani, B., & Matteson, E. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 259
“34 Imatinib also inhibits the platelet-derived growth factor (PDGF) receptor tyrosine kinase and has been evaluated in small open-label studies in SSc-ILD, 35 36 although no large randomised trials have been conducted and its efficacy is unclear.”
MethodKlinkhammer, B. M., Floege, J., & Boor, P. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.008 · Cited by 229
“A third trial in scleroderma using 200 mg/day imatinib for six months found a stabilized lung function and good drug tolerance but no significant improvement of skin involvement (Fraticelli et al., 2014).”
BackgroundThe Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 223
Systemic sclerosis: An update in 2016
Desbois, A. C., & Cacoub, P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.007 · Cited by 175
“It showed an improvement or stabilization of lung disease in 15% and 58% of patients, respectively [96].”
Metadata
- Authors
- Fraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., Gerli, R., Lunardi, C., Bombardieri, S., Malorni, W., Corvetta, A., Moroncini, G., & Gabrielli, A.
- Affiliations
- Azienda Ospedaliero-Universitaria delle Marche (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Università Cattolica del Sacro Cuore (IT)
- University of Milan (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
- University of L'Aquila (IT)
- University of Perugia (IT)
- University of Verona (IT)
- University of Pisa (IT)
- Istituto Superiore di Sanità (IT)
- Ospedale Infermi di Rimini (IT)
- Marche Polytechnic University (IT)
- Corresponding author
- Gabrielli, Armando
- ORCID
- Venue
- Arthritis Research & Therapy
- Published
- 2014-07-08
- Volume
- 16
- Issue
- 4
- Pages
- R144-R144
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC4227120
- OpenAlex
- W2126719591
- Cited by
- 108
- References
- 33
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 2 · 2022: 7 · 2021: 9 · 2020: 12 · 2019: 14 · 2018: 14 · 2017: 12 · 2016: 18 · 2015: 9
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- Istituto Superiore di Sanità
- Università Cattolica del Sacro Cuore
- Istituto Auxologico Italiano
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- systemic sclerosis, interstitial lung disease, imatinib, tyrosine kinase inhibitors, pulmonary involvement, lung function, forced vital capacity, diffusing capacity for carbon monoxide, high-resolution computed tomography, drug tolerability, skin involvement
- MeSH terms
- Imatinib Mesylate, Administration, Oral, Adult, Benzamides, Cyclophosphamide, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Pilot Projects, Piperazines, Pyrimidines, Respiratory Function Tests, Scleroderma, Systemic, Tomography, X-Ray Computed, Treatment Outcome, Lung Diseases, Interstitial, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.